plx2853
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 12, 2017 (NCT03297424)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Ovarian Epithelial · Phase 1/Phase 2
- Genital Neoplasms, Female · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1
- Lymphoma · Phase 1/Phase 2
- Lymphoma, Follicular · Phase 1/Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 1/Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 1
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 1/Phase 2
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05677373 | Phase 1/Phase 2 (Phase 2) | Jan 13, 2023 | National Cancer Institute (NCI) |
| NCT04556617 | Phase 1/Phase 2 (Phase 2) | Sep 21, 2020 | Plexxikon |
| NCT04493619 | Phase 1/Phase 2 (Phase 2) | Aug 11, 2020 | Plexxikon |
| NCT03787498 | Phase 1 | Mar 19, 2019 | Plexxikon |
| NCT03297424 | Phase 1/Phase 2 (Phase 2) | Sep 12, 2017 | Plexxikon |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Plexxikon | For profit | 4 | 4 | 2 | 2017 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1